C07D207/33

PHOSPHINE FREE COBALT BASED CATALYST, PROCESS FOR PREPARATION AND USE THEREOF

The present invention discloses a phosphine free cobalt based catalyst of formula (I) and a process for preparation thereof. The present invention further discloses a process for the synthesis of aromatic heterocyclic compounds of formula (II) and pyrazine derivative using the phosphine free cobalt based catalyst of formula (I).

PHOSPHINE FREE COBALT BASED CATALYST, PROCESS FOR PREPARATION AND USE THEREOF

The present invention discloses a phosphine free cobalt based catalyst of formula (I) and a process for preparation thereof. The present invention further discloses a process for the synthesis of aromatic heterocyclic compounds of formula (II) and pyrazine derivative using the phosphine free cobalt based catalyst of formula (I).

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT
20200216430 · 2020-07-09 ·

The present disclosure relates to reagents and method for performing trifluoromethylation, difluoromethylation or alkylation of aromatic or heteroaromatic rings in a redox-neutral manner without any catalyst which are enabled by light. In addition, there are methods for synthesizing the starting reagents used in the trifluoromethylation, difluoromethylation or alkylation reactions.

CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT
20200216430 · 2020-07-09 ·

The present disclosure relates to reagents and method for performing trifluoromethylation, difluoromethylation or alkylation of aromatic or heteroaromatic rings in a redox-neutral manner without any catalyst which are enabled by light. In addition, there are methods for synthesizing the starting reagents used in the trifluoromethylation, difluoromethylation or alkylation reactions.

Method for Preparation of Alkylated or Fluoro, Chloro and Fluorochloro Alkylated Compounds by Heterogeneous Cobalt Catalysis

The invention discloses a method for preparation of alkylated, fluoro alkylated, chloro alkylated and fluorochloro alkylated compounds by a heterogeneous Co-catalysed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl halides, fluoro alkyl halides, chloro alkyl halides or fluorochloro alkyl halides respectively.

GRP94 SELECTIVE INHIBITORS AND USES THEREOF

The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.

##STR00001##

GRP94 selective inhibitors and uses thereof

The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma. ##STR00001##

Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities

The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.